Rhophylac FDA Approval History
FDA Approved: Yes (First approved February 12, 2004)
Brand name: Rhophylac
Generic name: Rh0(D) immune globulin intravenous (human)
Dosage form: Injection
Company: ZLB Bioplasma AG, Switzerland
Treatment for: Rh-Isoimmunization, Immune Thrombocytopenia
Rhophylac (Rh0(D) immune globulin intravenous (human)) is indicated for the suppression of rhesus (Rh) isoimmunization in pregnancy, obstetric conditions and incompatible transfusions, and the treatment of immune thrombocytopenic purpura.
Development timeline for Rhophylac
| Date | Article |
|---|---|
| Apr 2, 2007 | Approval FDA Approves Rhophylac for the Treatment of Immune ThrombocytopenicPurpura (ITP) |
| Feb 12, 2004 | Approval Rhophylac ZLB Bioplasma AG, Switzerland - Treatment for Prevention of Rho(D) Sensitization |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
